Literature DB >> 11064188

Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis.

C J Jackson1, D C Lamb, D E Kelly, S L Kelly.   

Abstract

Azole antifungals are central to therapy and act by inhibiting a cytochrome P450, sterol 14-demethylase and blocking normal sterol synthesis. Our recent identification of a mycobacterial sterol biosynthetic pathway led us to probe the efficacy of a range of these compounds against Mycobacterium smegmatis. Several showed equivalent or greater inhibitory effects to those against Candida albicans, and bactericidal activity was demonstrated for four compounds, clotrimazole, econazole, miconazole and tebuconazole. The major drug used clinically, fluconazole, was ineffective. The results are discussed in the light of the world-wide spread of tuberculosis, including drug-resistant forms and the requirement for new drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064188     DOI: 10.1111/j.1574-6968.2000.tb09375.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  17 in total

1.  Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.

Authors:  Andrew G S Warrilow; Colin J Jackson; Josie E Parker; Timothy H Marczylo; Diane E Kelly; David C Lamb; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 2.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

3.  Advances in the treatment of pulmonary tuberculosis.

Authors:  Xia Zhang; Jing Guo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

Review 4.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

5.  Molecular detection of Cellulosimicrobium cellulans as the etiological agent of a chronic tongue ulcer in a human immunodeficiency virus-positive patient.

Authors:  Beate Heym; Pierre Gehanno; Véronique Friocourt; Marie-Elisabeth Bougnoux; Michèle Le Moal; Corinne Husson; Jacques Leibowitch; Marie-Hélène Nicolas-Chanoine
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

6.  An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae.

Authors:  Christopher R J Agnew; Andrew G S Warrilow; Nicholas M Burton; David C Lamb; Steven L Kelly; R Leo Brady
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

Review 7.  Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Paul R Ortiz de Montellano
Journal:  J Inorg Biochem       Date:  2018-01-12       Impact factor: 4.155

8.  Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.

Authors:  Kirsty J McLean; Paul Carroll; D Geraint Lewis; Adrian J Dunford; Harriet E Seward; Rajasekhar Neeli; Myles R Cheesman; Laurent Marsollier; Philip Douglas; W Ewen Smith; Ida Rosenkrands; Stewart T Cole; David Leys; Tanya Parish; Andrew W Munro
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

9.  Cloning and characterization of CYP51 from Mycobacterium avium.

Authors:  Michael P Pietila; Pawan K Vohra; Bharati Sanyal; Nancy L Wengenack; Sreekumar Raghavakaimal; Charles F Thomas
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-16       Impact factor: 6.914

10.  Effect of tetraconazole application on the soil microbial community.

Authors:  Wenwen Zhang; Jun Xu; Fengshou Dong; Xingang Liu; Ying Zhang; Xiaohu Wu; Yongquan Zheng
Journal:  Environ Sci Pollut Res Int       Date:  2014-04-06       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.